|
Vindesine
|
|
| Systematic (IUPAC) name | |
| methyl (5S,7S,9S)-9-[(2β,3β,4β,5α,12β,19α)-3-(aminocarbonyl)-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate | |
| Identifiers | |
| CAS number | 59917-39-4 |
| ATC code | L01CA03 |
| PubChem | 40839 |
| DrugBank | APRD00392 |
| Chemical data | |
| Formula | C43H55N5O7 |
| Mol. mass | 753.926 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 65-75% |
| Metabolism | Hepatic (CYP3A4-mediated) |
| Half life | 24 hours |
| Excretion | Biliary and renal |
| Therapeutic considerations | |
| Pregnancy cat. |
D(AU) |
| Legal status |
℞ Prescription only |
| Routes | Intravenous |
Vindesine is an anti-mitotic vinca alkaloid used in chemotherapy. It is used to treat many different types of cancer, including leukaemia, lymphoma, melanoma, breast cancer, and lung cancer.[1]
|
|||||||||||||||||||||||||||
| This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)




